Flu Vaccines 2019-20

Due to the extremely challenging 2018/19 flu season, the Buying Group made the decision to work with all four remaining flu vaccine companies for the 2019/20 season to ensure we are in a position to help our members no matter which supplier you decide to use next season.

Since we launched our offers in October 2018, two new vaccines have been licensed for the UK market. On 23 January 2019, NHS England confirmed which vaccines can be used for the 2019-20 season:

  • Patients aged 65 and over: Adjuvanted Trivalent (ATIV) or the cell based quadrivalent (QIVc). Both vaccines are manufactured by Seqirus and will be reimbursed.
  • At risk groups/eligible adults aged 64 and under: egg based quadrivalent (QIVe) or the cell based quadrivalent (QIVc). QIVe vaccines are available from MASTA, Mylan and Sanofi. The QIVc is only available from Seqirus. Both the QIVe and QIVc vaccines will be reimbursed. Since we released our original offer information, Mylan has informed us that children aged 3-17 can now be given either of their QIVe vaccines.

The high-dose trivalent vaccine (TIV-HD), which JCVI also advised as equally suitable for use in those aged 65 years and over, has now been licensed for use in the UK but has a significantly higher list price than the equally suitable vaccines. This vaccine will not be commissioned by NHS England or reimbursed for use in the NHS Influenza vaccination programme in 2019/20.

Please read the latest updates from NHS England for more information:

Published update 17 July 2019
Published update 23 January 2019

To view the offers for the 2019-20 season, visit the Flu Vaccines page in the Suppliers section of the website. You will need to be logged in to view this information.

Products & Services